Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs.

Wu CP, Lusvarghi S, Tseng PJ, Hsiao SH, Huang YH, Hung TH, Ambudkar SV.

Am J Cancer Res. 2020 Jan 1;10(1):164-178. eCollection 2020.

2.

Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models.

Lusvarghi S, Robey RW, Gottesman MM, Ambudkar SV.

F1000Res. 2020 Jan 13;9. pii: F1000 Faculty Rev-17. doi: 10.12688/f1000research.21295.1. eCollection 2020. Review.

3.

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.

Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS.

Cancers (Basel). 2020 Jan 12;12(1). pii: E186. doi: 10.3390/cancers12010186.

4.

The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.

Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV.

Int J Mol Sci. 2019 Dec 29;21(1). pii: E238. doi: 10.3390/ijms21010238.

5.

ATP-dependent thermostabilization of human P-glycoprotein (ABCB1) is blocked by modulators.

Lusvarghi S, Ambudkar SV.

Biochem J. 2019 Dec 19;476(24):3737-3750. doi: 10.1042/BCJ20190736.

PMID:
31774117
6.

ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942.

Sava GP, Fan H, Fisher RA, Lusvarghi S, Pancholi S, Ambudkar SV, Martin LA, Charles Coombes R, Buluwela L, Ali S.

Oncogene. 2020 Jan;39(3):651-663. doi: 10.1038/s41388-019-1008-y. Epub 2019 Sep 17.

7.

A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.

Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD.

Mol Pharmacol. 2019 Nov;96(5):629-640. doi: 10.1124/mol.119.115964. Epub 2019 Sep 12.

8.

Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1).

Sajid A, Raju N, Lusvarghi S, Vahedi S, Swenson RE, Ambudkar SV.

Drug Metab Dispos. 2019 Oct;47(10):1013-1023. doi: 10.1124/dmd.119.087734. Epub 2019 Aug 1.

9.

Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.

Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV.

Mol Pharm. 2019 Jul 1;16(7):3040-3052. doi: 10.1021/acs.molpharmaceut.9b00274. Epub 2019 Jun 4.

PMID:
31117741
10.

Large-scale purification of functional human P-glycoprotein (ABCB1).

Nandigama K, Lusvarghi S, Shukla S, Ambudkar SV.

Protein Expr Purif. 2019 Jul;159:60-68. doi: 10.1016/j.pep.2019.03.002. Epub 2019 Mar 6.

PMID:
30851394
11.

The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.

Hsiao SH, Lusvarghi S, Huang YH, Ambudkar SV, Hsu SC, Wu CP.

Cancer Lett. 2019 Mar 31;445:34-44. doi: 10.1016/j.canlet.2019.01.001. Epub 2019 Jan 11.

PMID:
30639533
12.

Evidence for the critical role of transmembrane helices 1 and 7 in substrate transport by human P-glycoprotein (ABCB1).

Sajid A, Lusvarghi S, Chufan EE, Ambudkar SV.

PLoS One. 2018 Sep 28;13(9):e0204693. doi: 10.1371/journal.pone.0204693. eCollection 2018.

13.

Mapping discontinuous epitopes for MRK-16, UIC2 and 4E3 antibodies to extracellular loops 1 and 4 of human P-glycoprotein.

Vahedi S, Lusvarghi S, Pluchino K, Shafrir Y, Durell SR, Gottesman MM, Ambudkar SV.

Sci Rep. 2018 Aug 24;8(1):12716. doi: 10.1038/s41598-018-30984-8.

14.

Chemical and Biophysical Approaches for Complete Characterization of Lectin-Carbohydrate Interactions.

Lusvarghi S, Ghirlando R, Davison JR, Bewley CA.

Methods Enzymol. 2018;598:3-35. doi: 10.1016/bs.mie.2017.06.010. Epub 2017 Jul 23.

15.

Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential.

Lusvarghi S, Bewley CA.

Viruses. 2016 Oct 24;8(10). pii: E296. Review.

16.

Binding Site Geometry and Subdomain Valency Control Effects of Neutralizing Lectins on HIV-1 Viral Particles.

Lusvarghi S, Lohith K, Morin-Leisk J, Ghirlando R, Hinshaw JE, Bewley CA.

ACS Infect Dis. 2016 Nov 11;2(11):882-891. Epub 2016 Oct 3.

PMID:
27669574
17.

Correction: Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.

Mason RD, Welles HC, Adams C, Chakrabarti BK, Gorman J, Zhou T, Nguyen R, O'Dell S, Lusvarghi S, Bewley CA, Li H, Shaw GM, Sheng Z, Shapiro L, Wyatt R, Kwong PD, Mascola JR, Roederer M.

PLoS Pathog. 2016 May 24;12(5):e1005674. doi: 10.1371/journal.ppat.1005674. eCollection 2016 May.

18.

Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.

Mason RD, Welles HC, Adams C, Chakrabarti BK, Gorman J, Zhou T, Nguyen R, O'Dell S, Lusvarghi S, Bewley CA, Li H, Shaw GM, Sheng Z, Shapiro L, Wyatt R, Kwong PD, Mascola JR, Roederer M.

PLoS Pathog. 2016 Apr 11;12(4):e1005537. doi: 10.1371/journal.ppat.1005537. eCollection 2016 Apr. Erratum in: PLoS Pathog. 2016 May;12(5):e1005674.

19.

Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry.

Dogo-Isonagie C, Lee SL, Lohith K, Liu H, Mandadapu SR, Lusvarghi S, O'Connor RD, Bewley CA.

Bioorg Med Chem. 2016 Apr 15;24(8):1718-28. doi: 10.1016/j.bmc.2016.02.044. Epub 2016 Mar 3.

PMID:
26968647
20.

Novel Biochemical Tools for Probing HIV RNA Structure.

Rausch JW, Sztuba-Solinska J, Lusvarghi S, Le Grice SF.

Methods Mol Biol. 2016;1354:91-117. doi: 10.1007/978-1-4939-3046-3_7.

Supplemental Content

Loading ...
Support Center